Emisphere Technologies/J Biologics
Executive Summary
Firms collaborating on an oral Factor IX formulation to treat hemophilia B. Under the agreement, Hawthorne, N.Y.-based Emisphere will provide its Oral Delivery System in return for funding from New York City-based J. ODS encapsulates therapeutic products in amino acid-based microspheres that allow the drug to enter the bloodstream unchanged from its passage through the gastrointestinal tract. J is a private, for-profit organization that supports R&D efforts related to hemophilia and blood disorders. The Factor IX is being provided under a subcontract with the American Red Cross.